Posts

Staph Aureus on the Skin Associated With Severe Food Allergic Reactions Via a Cascade: IL-33, IL-3, IL-4

Predicting Outcomes in Common Variable Immunodeficiency (CVID)

New Risk Score Predicts Nasal Polyp Recurrence After Sinus Surgery for CRSwNP

Oral ITK Inhibitor Soquelitinib in Development for Atopic Dermatitis

Monoclonal Antibody Targeting OX40L (Amlitelimab) In Development for Atopic Dermatitis

EoE Pipeline Update: Dupilumab Leads, But Exciting Contenders Are Closing In

I-SEE the Future: New Tool (I-SEE index) Changes How We Manage Eosinophilic Esophagitis (EoE)

Once-yearly local therapy for EoE: Long-acting, injectable fluticasone in development for treating eosinophilic esophagitis (EoE)

Twice-a-Year Relief: Depemokimab Poised to Transform Nasal Polyps Care

New HAE Trials and Therapies on the Horizon as of 2026

EU Greenlights Dawnzera™: RNA Therapy for Hereditary Angioedema, Following US Approval

The "Safer" Hair Dye Ingredient That's Now the 2025 Contact Allergen of the Year: Toluene-2,5-diamine sulfate (PTDS)

The First FDA-Approved Treatment for Chronic Hand Eczema: Anzupgo (Delgocitinib) Cream, a pan-JAK inhibitor

"Leaky Gut" Link? New Study Shows Elevated Zonulin in Chronic Spontaneous Urticaria

Briquilimab Antibody Delivers Rapid, Lasting Relief in Chronic Urticaria Trials (targeting KIT (CD117)

New asthma treatment in development: once-daily oral STAT6 degrader for eosinophilic asthma.

Anti-IL2 Antibody Rezpegaldesleukin Shows Promise in Atopic Dermatitis and Comorbid Asthma (Possible Dual Indication)

Biologic Management in Severe Asthma for Adults - New Guideline by CHEST in 2026

"Pseudo leukotrienes" øLTs - new inflammation-triggering molecules - may play a role in asthma

Metabolomics blood test predicts asthma exacerbation risk up to 5 years in advance with 90% accuracy